JARISLOWSKY FRASER Ltd Grows Stock Holdings in Haleon plc (NYSE:HLN)

JARISLOWSKY FRASER Ltd lifted its position in Haleon plc (NYSE:HLN) by 8.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 697,108 shares of the company’s stock after buying an additional 56,615 shares during the period. JARISLOWSKY FRASER Ltd’s holdings in Haleon were worth $6,650,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of HLN. Wellington Management Group LLP increased its position in shares of Haleon by 67.5% during the fourth quarter. Wellington Management Group LLP now owns 15,328,325 shares of the company’s stock worth $146,232,000 after purchasing an additional 6,175,835 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Haleon during the 4th quarter worth $42,193,000. FMR LLC increased its position in Haleon by 3.7% during the 4th quarter. FMR LLC now owns 108,827,814 shares of the company’s stock valued at $1,038,217,000 after buying an additional 3,909,545 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in Haleon in the fourth quarter valued at about $39,628,000. Finally, Northern Trust Corp boosted its holdings in Haleon by 27.7% in the fourth quarter. Northern Trust Corp now owns 5,412,542 shares of the company’s stock worth $51,636,000 after acquiring an additional 1,172,931 shares in the last quarter. Institutional investors own 6.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Barclays reaffirmed an “overweight” rating on shares of Haleon in a research report on Tuesday. Hsbc Global Res cut shares of Haleon from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Haleon in a report on Monday, March 3rd. Morgan Stanley upgraded Haleon from an “equal weight” rating to an “overweight” rating and set a $11.25 target price for the company in a research note on Friday. Finally, HSBC reiterated a “hold” rating on shares of Haleon in a research note on Wednesday, March 5th. Five research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $11.25.

Haleon Price Performance

Shares of HLN opened at $10.75 on Friday. The company has a market capitalization of $48.48 billion, a P/E ratio of 31.62, a P/E/G ratio of 2.82 and a beta of 0.24. The business’s 50-day moving average is $10.20 and its two-hundred day moving average is $9.84. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. Haleon plc has a fifty-two week low of $8.24 and a fifty-two week high of $10.85.

Haleon (NYSE:HLN) last announced its quarterly earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The company had revenue of $3.54 billion during the quarter, compared to analysts’ expectations of $3.38 billion. Research analysts predict that Haleon plc will post 0.43 earnings per share for the current year.

Haleon Increases Dividend

The company also recently declared a — dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be given a dividend of $0.1166 per share. This represents a yield of 1.6%. The ex-dividend date is Friday, April 25th. This is a positive change from Haleon’s previous — dividend of $0.05. Haleon’s dividend payout ratio (DPR) is currently 58.97%.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.